Skip to search formSkip to main contentSkip to account menu

maxacalcitol

Known as: 22-oxacalcitriol, 1,25-dihydroxy-22-oxavitamin D3, maxacalcitriol 
National Institutes of Health

Related topics

Related topics

6 relations

Broader (4)

Anticarcinogenic AgentsAntineoplastic AgentsCalcitriolDermatologic Agents

Narrower (1)

Oxarol
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
22‐Oxa‐1,25‐dihydroxyvitamin D3 efficiently inhibits tumor growth in inoculated mice and primary histoculutre of cholangiocarcinoma
It is well known that 1α,25‐Dihydroxyvitamin D3(1,25[OH]2D3) restrains cell proliferation and induces differentiation and… 
2008
2008
Clinical effect of vitamin D3 analogues is not inactivated by subsequent UV exposure
Background: Combining phototherapy with topical vitamin D3 analogues is a useful therapy for the treatment of psoriasis by… 
2007
2007
Clinical Features and Hyperplastic Patterns of Parathyroid Glands in Hemodialysis Patients With Advanced Secondary Hyperparathyroidism Refractory to Maxacalcitol Treatment and Required…
Abstract:  We have previously suggested that when parathyroid glands progress to nodular hyperplasia, secondary… 
2001
2001
Clinical effects of maxacalcitol on secondary hyperparathyroidism of uremic patients.
Maxacalcitol (22-oxacalcitriol [OCT]) is a newly developed vitamin D analogue in Japan. OCT has shown less calcemic action and a… 
1997
1997
1,25-Dihydroxyvitamin D3 and a new analogue, 22-oxacalcitriol, modulate proliferation and interleukin-8 secretion of normal human keratinocytes.
1997
1997
1,25-dihydroxyvitamin D3 induction of nerve growth factor in L929 mouse fibroblasts: effect of vitamin D receptor regulation and potency of vitamin D3 analogs.
Decreased nerve growth factor (NGF) synthesis in the hippocampus and reduced nerve growth factor receptor immunoreactivity in CH1… 
1996
1996
A new human breast cancer cell line, KPL-3C, secretes parathyroid hormone-related protein and produces tumours associated with microcalcifications in nude mice.
Parathyroid hormone-related protein (PTHrP) is the main cause of humoral hypercalcaemia of malignancy (HHM). We recently… 
1993
1993
The 1,25-dihydroxy-vitamin D3 receptor is phosphorylated in response to 1,25-dihydroxy-vitamin D3 and 22-oxacalcitriol in rat osteoblasts, and by casein kinase II, in vitro.
We analyzed the endogenous nuclear 1,25-dihydroxy-vitamin D3 (1,25(OH)2D3) receptor (VDR) in rat osteosarcoma (ROS 17/2.8) cells… 
Highly Cited
1991
Highly Cited
1991
A novel vitamin D3 analog, 22-oxa-1,25-dihydroxyvitamin D3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia.
Although 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] has been shown to inhibit the growth of certain malignant cells, its… 
1991
1991
The activity of 22-oxacalcitriol in osteoblast-like (ROS 17/2.8) cells.
22-Oxacalcitriol (OCT), a synthetic vitamin D analog, can mimic the ability of 1,25-dihydroxyvitamin D3[1,25-(OH)2D3] to… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)